# BNIP2

## Overview
BNIP2 (BCL2 interacting protein 2) is a gene that encodes a protein involved in various cellular processes, including apoptosis regulation and cytoskeletal organization. The protein, also named BNIP2, is characterized by its BNIP2 and Cdc42GAP homology (BCH) domain, which facilitates interactions with proteins such as Cdc42 and Cdc42GAP, playing a crucial role in cell morphology and motility (Zhou2005BNIP2). As a pro-apoptotic member of the Bcl-2 family, BNIP2 is implicated in cell death pathways and is known to possess GTPase-activating activity, influencing cytoskeletal dynamics and cellular signaling (Low2000The). The protein's interactions are modulated by post-translational modifications, such as tyrosine phosphorylation, which regulate its binding affinity and functional roles (Low1999Tyrosine). BNIP2's involvement in apoptosis and cytoskeletal rearrangement underscores its significance in maintaining cellular homeostasis and its potential implications in cancer therapy (Belcredito2001Estrogen; Chai2011miR20a).

## Structure
BNIP2 (BCL2 interacting protein 2) is characterized by the presence of a BNIP2 and Cdc42GAP homology (BCH) domain, which is crucial for its interactions with other proteins, such as Cdc42 and Cdc42GAP. This domain contains a unique Cdc42-binding motif, distinct from the conventional CRIB motif found in other Cdc42 effectors, which is essential for BNIP2's role in inducing cell elongation and membrane protrusions (Zhou2005BNIP2). The BCH domain also includes a core binding region, specifically the sequence 285 VPMEYVGI 292, which is critical for binding Cdc42 and inducing morphological changes (Zhou2005BNIP2).

BNIP2 undergoes post-translational modifications, such as tyrosine phosphorylation by the fibroblast growth factor receptor-1 (FGFR-1). This phosphorylation modulates its interaction with Cdc42GAP and Cdc42, acting as a regulatory switch that affects its binding affinity (Low1999Tyrosine). The protein also contains a single EF-hand calcium-binding domain, contributing to its structural and functional properties (Low1999Tyrosine).

BNIP2 can exist in multiple splice variant isoforms, which may influence its functional interactions and regulatory roles in cellular signaling pathways (Low1999Tyrosine).

## Function
BNIP2 (BCL2 interacting protein 2) is involved in several critical cellular processes, including apoptosis regulation and cytoskeletal organization. It functions as a pro-apoptotic member of the Bcl-2 family, interacting with proteins such as BCL2 and adenovirus E1B 19 kDa, which are involved in cell death pathways (Valencia2007Cleavage). BNIP2 is known to possess GTPase-activating activity toward the small GTPase Cdc42, a protein involved in cytoskeletal organization, gene transcription regulation, and cell cycle progression (Low2000The). The BCH domain of BNIP2 is crucial for its interactions with Cdc42GAP, mediating both homophilic and heterophilic interactions, which are essential for its role in modulating Cdc42 activity (Low2000The).

In healthy human cells, BNIP2 is active in the cytoplasm and associated with the Golgi apparatus, where it influences cell morphology and motility (Valencia2007Cleavage). The protein's interactions and regulatory functions suggest its involvement in maintaining cellular homeostasis and influencing organismal development through its impact on cell shape and movement (Low2000The). BNIP2's role in apoptosis and cytoskeletal dynamics highlights its importance in cellular responses and developmental processes.

## Clinical Significance
Alterations in the expression or interaction of the BNIP2 gene have significant clinical implications, particularly in the context of cancer. BNIP2 is a pro-apoptotic factor, and its expression is regulated by various stimuli, including miR-20a, which targets BNIP2 and contributes to chemotherapeutic resistance in colorectal adenocarcinoma. The downregulation of BNIP2 by miR-20a disrupts the balance between pro-apoptotic and anti-apoptotic factors, leading to increased survival of cancer cells under chemotherapeutic stress (Chai2011miR20a).

In neuroblastoma cells, overexpression of BNIP2 leads to increased cell death, which can be counteracted by the anti-apoptotic protein Bcl-2, suggesting a potential interaction that could be exploited in therapeutic strategies (Belcredito2001Estrogen). Additionally, BNIP2 is a substrate for granzyme B, a protease involved in apoptosis induction by natural killer cells. The cleavage of BNIP2 by granzyme B may enhance its pro-apoptotic activity, although its exact role in apoptosis induction remains unclear (Scott2010Identification).

These findings highlight the potential of targeting BNIP2 interactions and expression levels in cancer treatment, particularly in overcoming drug resistance and regulating apoptosis in tumor cells.

## Interactions
BNIP2 (BCL2 interacting protein 2) is involved in several protein interactions primarily through its BNIP-2 and Cdc42GAP homology (BCH) domain. It interacts with Cdc42GAP and Cdc42, forming complexes that influence the GTPase activity of Cdc42. BNIP2 can bind to Cdc42 regardless of its nucleotide-binding status, and this interaction is crucial for inducing cell elongation and membrane protrusions (Low1999Tyrosine; Zhou2005BNIP2). The interaction with Cdc42 is mediated by a unique Cdc42-binding motif within the BCH domain, distinct from the CRIB motif found in other Cdc42 effectors (Zhou2005BNIP2).

BNIP2's interaction with Cdc42GAP is modulated by tyrosine phosphorylation by fibroblast growth factor receptor-1 (FGFR-1), which prevents BNIP2 from binding to Cdc42GAP and Cdc42, thus acting as a regulatory switch (Low1999Tyrosine). The BCH domain of BNIP2 also allows it to form homophilic associations and heterophilic interactions with Cdc42GAP, suggesting a role in regulating Cdc42 activity (Low2000The). BNIP2's interactions are significant for cellular processes such as cytoskeletal rearrangement and cell morphology changes, highlighting its role in cell signaling pathways (Zhou2005BNIP2).


## References


[1. (Scott2010Identification) Gina B. Scott, Paul A. Bowles, Erica B. Wilson, Josephine L. Meade, Boon Chuan Low, Adam Davison, G. Eric Blair, and Graham P. Cook. Identification of the bcl2/adenovirus e1b-19k protein-interacting protein 2 (bnip-2) as a granzyme b target during human natural killer cell-mediated killing. Biochemical Journal, 431(3):423–431, October 2010. URL: http://dx.doi.org/10.1042/bj20091073, doi:10.1042/bj20091073. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20091073)

[2. (Zhou2005BNIP2) Yi Ting Zhou, Graeme R. Guy, and Boon Chuan Low. Bnip-2 induces cell elongation and membrane protrusions by interacting with cdc42 via a unique cdc42-binding motif within its bnip-2 and cdc42gap homology domain. Experimental Cell Research, 303(2):263–274, February 2005. URL: http://dx.doi.org/10.1016/j.yexcr.2004.08.044, doi:10.1016/j.yexcr.2004.08.044. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.yexcr.2004.08.044)

[3. (Low1999Tyrosine) Boon Chuan Low, Yoon Pin Lim, Jormay Lim, Esther Sook Miin Wong, and Graeme R. Guy. Tyrosine phosphorylation of the bcl-2-associated protein bnip-2 by fibroblast growth factor receptor-1 prevents its binding to cdc42gap and cdc42. Journal of Biological Chemistry, 274(46):33123–33130, November 1999. URL: http://dx.doi.org/10.1074/jbc.274.46.33123, doi:10.1074/jbc.274.46.33123. This article has 41 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.274.46.33123)

[4. (Valencia2007Cleavage) C. Alexander Valencia, Steven W. Cotten, and Rihe Liu. Cleavage of bnip-2 and bnip-xl by caspases. Biochemical and Biophysical Research Communications, 364(3):495–501, December 2007. URL: http://dx.doi.org/10.1016/j.bbrc.2007.10.018, doi:10.1016/j.bbrc.2007.10.018. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2007.10.018)

[5. (Belcredito2001Estrogen) Silvia Belcredito, Elisabetta Vegeto, Alessia Brusadelli, Serena Ghisletti, Paola Mussi, Paolo Ciana, and Adriana Maggi. Estrogen neuroprotection: the involvement of the bcl-2 binding protein bnip2. Brain Research Reviews, 37(1–3):335–342, November 2001. URL: http://dx.doi.org/10.1016/s0165-0173(01)00138-2, doi:10.1016/s0165-0173(01)00138-2. This article has 28 citations.](https://doi.org/10.1016/s0165-0173(01)00138-2)

[6. (Low2000The) Boon Chuan Low, Kah Tong Seow, and Graeme R. Guy. The bnip-2 and cdc42gap homology domain of bnip-2 mediates its homophilic association and heterophilic interaction with cdc42gap. Journal of Biological Chemistry, 275(48):37742–37751, December 2000. URL: http://dx.doi.org/10.1074/jbc.m004897200, doi:10.1074/jbc.m004897200. This article has 41 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m004897200)

[7. (Chai2011miR20a) Huijuan Chai, Min Liu, Ruiqing Tian, Xin Li, and Hua Tang. Mir-20a targets bnip2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma sw480 and sw620 cell lines. Acta Biochimica et Biophysica Sinica, 43(3):217–225, March 2011. URL: http://dx.doi.org/10.1093/abbs/gmq125, doi:10.1093/abbs/gmq125. This article has 91 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/abbs/gmq125)